Quintet Private Bank Europe S.A. Has $27.09 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Quintet Private Bank Europe S.A. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,697 shares of the medical equipment provider's stock after buying an additional 927 shares during the quarter. Intuitive Surgical comprises 1.6% of Quintet Private Bank Europe S.A.'s portfolio, making the stock its 23rd largest holding. Quintet Private Bank Europe S.A.'s holdings in Intuitive Surgical were worth $27,090,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Onefund LLC increased its position in Intuitive Surgical by 1.9% during the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after buying an additional 18 shares during the last quarter. AlphaCore Capital LLC boosted its holdings in Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after acquiring an additional 18 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Intuitive Surgical by 2.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after acquiring an additional 19 shares during the period. Accredited Investors Inc. boosted its holdings in Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after acquiring an additional 19 shares during the period. Finally, Second Line Capital LLC boosted its holdings in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after acquiring an additional 19 shares during the period. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Barclays decreased their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Evercore ISI decreased their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. Truist Financial decreased their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, BTIG Research set a $560.00 price target on shares of Intuitive Surgical and gave the company a "buy" rating in a report on Monday, April 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $588.95.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $0.82 during mid-day trading on Friday, hitting $512.18. The company had a trading volume of 2,181,892 shares, compared to its average volume of 1,672,886. The business's 50-day simple moving average is $525.48 and its 200-day simple moving average is $538.67. Intuitive Surgical, Inc. has a 12 month low of $413.82 and a 12 month high of $616.00. The firm has a market cap of $183.57 billion, a P/E ratio of 79.90, a PEG ratio of 5.85 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The firm had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the business posted $1.50 earnings per share. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the sale, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,695,113.84. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the sale, the director now directly owns 6,371 shares of the company's stock, valued at approximately $3,312,920. The trade was a 27.36% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,998 shares of company stock valued at $2,611,577. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.